CCM
JBIO

Corsair Capital Management’s Jade Biosciences JBIO Stock Holding History

Corsair Capital Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-289
Closed -$21.1K – 121
2024
Q3 		$21.1K Sell
289
-285
-50% -$18.4K 0.01% 116
2024
Q2 		$33.4K Buy
+574
New +$381K 0.01% 100

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AI
Allostery Investments Stamford, Connecticut $7.85M AUM

Corsair Capital Management's JBIO Position: Q4 2024 in Review

Corsair Capital Management sold out of Jade Biosciences (JBIO) in Q4 2024, closing a stake of 289 shares — an estimated $21.1K sold.

Corsair Capital Management first reported a position in JBIO in Q2 2024 and held it in 2 quarters. The position peaked at $33.4K in Q2 2024. 78 funds tracked by Wall St. Rank hold JBIO as of Q4 2024.

  • Corsair Capital Management reported no remaining Jade Biosciences position as of Q4 2024 after selling out during the quarter.
  • Corsair Capital Management sold 289 Jade Biosciences shares in Q4 2024, an estimated $21.1K.
  • Corsair Capital Management first reported a position in Jade Biosciences in Q2 2024 and held it in 2 quarters.
  • Corsair Capital Management's Jade Biosciences position peaked at $33.4K in Q2 2024.
  • 78 funds tracked by Wall St. Rank held Jade Biosciences as of Q4 2024.

Based on Corsair Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.